Purple Biotech Valuation
| KTOV Stock | ILA 7.20 0.20 2.70% |
At this time, the company appears to be overvalued. Purple Biotech holds a recent Real Value of 7.1 per share. The prevailing price of the company is 7.2. Our model determines the value of Purple Biotech from analyzing the company fundamentals such as Shares Owned By Institutions of 1.22 %, shares outstanding of 172.11 M, and Return On Equity of -0.92 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Purple Biotech's price fluctuation is very risky at this time. Calculation of the real value of Purple Biotech is based on 3 months time horizon. Increasing Purple Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Purple Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Purple Stock. However, Purple Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 7.2 | Real 7.1 | Hype 7.4 | Naive 8.75 |
The real value of Purple Stock, also known as its intrinsic value, is the underlying worth of Purple Biotech Company, which is reflected in its stock price. It is based on Purple Biotech's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Purple Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Purple Biotech helps investors to forecast how Purple stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Purple Biotech more accurately as focusing exclusively on Purple Biotech's fundamentals will not take into account other important factors: Purple Biotech Total Value Analysis
Purple Biotech is now forecasted to have takeover price of 0 with market capitalization of 227.01 M, debt of 117 K, and cash on hands of 63.01 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Purple Biotech fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
0 | 227.01 M | 117 K | 63.01 M |
Purple Biotech Investor Information
The company has price-to-book ratio of 1.27. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Purple Biotech recorded a loss per share of 0.17. The entity last dividend was issued on the 30th of October 2012. The firm had 1:20 split on the 6th of January 2019. Purple Biotech is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Purple Biotech Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Purple Biotech has an asset utilization ratio of 6.79 percent. This suggests that the Company is making 0.0679 for each dollar of assets. An increasing asset utilization means that Purple Biotech is more efficient with each dollar of assets it utilizes for everyday operations.Purple Biotech Ownership Allocation
Purple Biotech owns a total of 172.11 Million outstanding shares. Roughly 98.66 pct. of Purple Biotech outstanding shares are held by general public with 0.12 % owned by insiders and only 1.22 (%) by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Purple Biotech Profitability Analysis
The company reported the revenue of 1000 K. Net Loss for the year was (5.85 M) with profit before overhead, payroll, taxes, and interest of 1000 K.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Purple Biotech's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Purple Biotech and how it compares across the competition.
About Purple Biotech Valuation
The stock valuation mechanism determines Purple Biotech's current worth on a weekly basis. Our valuation model uses a comparative analysis of Purple Biotech. We calculate exposure to Purple Biotech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Purple Biotech's related companies.Kitov Pharma Ltd, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. The company was formerly known as Kitov Pharmaceuticals Holdings Ltd. and changed its name to Kitov Pharma Ltd in January 2018. KITOV PHARMA operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 9 people.
8 Steps to conduct Purple Biotech's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Purple Biotech's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Purple Biotech's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Purple Biotech's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Purple Biotech's revenue streams: Identify Purple Biotech's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Purple Biotech's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Purple Biotech's growth potential: Evaluate Purple Biotech's management, business model, and growth potential.
- Determine Purple Biotech's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Purple Biotech's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Purple Stock analysis
When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |